Get the Stockscreener App
11.27
3.01%
-0.35
After Hours:
11.21
-0.06
-0.53%
Aurinia Pharmaceuticals Inc stock is traded at $11.27, with a volume of 1.34M.
It is down -3.01% in the last 24 hours and down -7.77% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$11.62
Open:
$11.64
24h Volume:
1.34M
Relative Volume:
0.66
Market Cap:
$1.48B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
26.21
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
-0.70%
1M Performance:
-7.77%
6M Performance:
+53.54%
1Y Performance:
+61.46%
1-Day Range:
$11.19
$11.64
1-Week Range:
$11.07
$11.87
52-Week Range:
$6.55
$13.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
11.27 | 1.53B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Can Aurinia Pharmaceuticals Inc. (IKAP) stock reach $200 price targetTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Statistical indicators supporting Aurinia Pharmaceuticals Inc.’s strengthTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Technical analysis overview for Aurinia Pharmaceuticals Inc. stockTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Real time breakdown of Aurinia Pharmaceuticals Inc. stock performance2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
What the charts say about Aurinia Pharmaceuticals Inc. todayRate Hike & Daily Stock Trend Reports - newser.com
Market reaction to Aurinia Pharmaceuticals Inc.’s recent newsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Predicting Aurinia Pharmaceuticals Inc. trend using moving averages2025 Geopolitical Influence & Weekly High Momentum Picks - newser.com
Aurinia Pharmaceuticals' (AUPH) "Hold (C)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Analyzing net buyer seller activity in Aurinia Pharmaceuticals Inc.2025 Fundamental Recap & Free Community Consensus Stock Picks - newser.com
Can trapped investors hope for a rebound in Aurinia Pharmaceuticals Inc.Weekly Profit Recap & Fast Moving Stock Trade Plans - newser.com
Combining machine learning predictions for Aurinia Pharmaceuticals Inc.Portfolio Return Report & Stock Portfolio Risk Management - newser.com
Will Aurinia Pharmaceuticals Inc. price bounce be sustainableMarket Risk Summary & Proven Capital Preservation Methods - newser.com
Is Shriram Asset Management Company Limited a Hybrid Growth Value Stock Worth HoldingPrice Gap Trading Strategies & Achieve Triple Digit Returns - earlytimes.in
Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
How Aurinia Pharmaceuticals Inc. (IKAP) stock compares with top peers2025 Short Interest & Community Consensus Picks - newser.com
Pattern recognition hints at Aurinia Pharmaceuticals Inc. upsidePortfolio Update Report & Proven Capital Preservation Methods - newser.com
Using AI based signals to follow Aurinia Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
Forecasting Aurinia Pharmaceuticals Inc. price range with options dataQuarterly Market Review & High Return Trade Opportunity Guides - newser.com
Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)? - Sahm
How high can Aurinia Pharmaceuticals Inc. stock go2025 Momentum Check & High Accuracy Investment Signals - newser.com
Smart tools for monitoring Aurinia Pharmaceuticals Inc.’s price actionGap Up & Verified Stock Trade Ideas - newser.com
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Aurinia Pharmaceuticals Hits Day Low of $11.04 Amid Price Pressure - Markets Mojo
Aurinia responds after top FDA official’s comment on lead drug - MSN
Aurinia Sinks After FDA Official Questions Its Drug in Post - MSN
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech - BioPharma Dive
Why retail investors pile into Aurinia Pharmaceuticals Inc. stock2025 Key Lessons & Technical Pattern Based Signals - newser.com
Can swing trading help recover from Aurinia Pharmaceuticals Inc. lossesJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Will earnings trigger a reversal in Aurinia Pharmaceuticals Inc.Market Trend Review & Smart Investment Allocation Insights - newser.com
What analysts say about Aurinia Pharmaceuticals Inc stockEconomic Impact on Stocks & Double Digit Profit Strategies - earlytimes.in
Aurinia Defends Benefit/Risk Profile of Lupus Nephritis Treatment After FDA Official's Retracted LinkedIn Post - MarketScreener
Aurinia Pharma rises after defending lupus drug - TradingView
Aurinia Sinks After FDA Official Questions Its Drug on LinkedIn - Bloomberg.com
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery - MSN
Jefferies reiterates Hold rating on Aurinia Pharmaceuticals stock at $10 price target - Investing.com Canada
Aurinia Pharmaceuticals stock hits 52-week high at 13.45 USD By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):